Experimental cell therapy targets rare Muscle-Weakening disease
Disease control
Completed
This early-phase study tested a new cell therapy called MuSK-CAART in 7 people with a rare, severe form of myasthenia gravis caused by antibodies attacking the MuSK protein. The treatment uses the patient's own immune cells, modified to target and destroy the antibody-producing c…
Phase: PHASE1 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC